Comparative Pharmacology
Head-to-head clinical analysis: PONLIMSI versus SPRYCEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PONLIMSI versus SPRYCEL.
PONLIMSI vs SPRYCEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
Dasatinib is a dual tyrosine kinase inhibitor targeting BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. It binds to the ATP-binding site of BCR-ABL and inhibits proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
100 mg orally once daily, with or without food.
None Documented
None Documented
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Terminal elimination half-life is approximately 3–4 hours for dasatinib, with a longer half-life of 8–10 hours for its active metabolite; clinical context: supports twice-daily dosing.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <10% of the dose.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor